<DOC>
	<DOCNO>NCT00019097</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor cell may make body build immune response kill tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation plus vaccine therapy chemotherapy treat patient multiple myeloma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether autologous myeloma-derived immunoglobulin idiotype conjugate keyhole limpet hemocyanin plus sargramostim ( GM-CSF ) induce cellular humoral immunity unique idiotype express surface myeloma cell patient multiple myeloma undergoing second autologous peripheral blood stem cell transplantation . II . Determine clinical efficacy safety regimen patient . PROTOCOL OUTLINE : Within 6 month first autologous peripheral blood stem cell transplantation ( APBSCT ) , patient receive melphalan IV 30 minute day -2 second APBSCT day 0 . Sargramostim ( GM-CSF ) administer subcutaneously ( SC ) begin day 1 continue blood count recover . Patients also assign 1 3 vaccination group . Group 1 : Patients receive autologous myeloma-derived immunoglobulin idiotype conjugate keyhole limpet hemocyanin ( Id-KLH ) SC day 1 GM-CSF SC day 1-4 month 2 , 3 , 5 second APBSCT total 3 vaccination . Group 2 : Patients receive Id-KLH SC day 1 GM-CSF SC day 1-4 month 2 , 3 , 4 , 5 , 6 , 8 second APBSCT total 6 vaccination . Group 3 : Patients receive Id-KLH SC day 1 GM-CSF SC day 1-4 week -8 , -6 , -2 month 2 , 3 , 5 second APBSCT total 6 vaccination . Patients follow within 3 month every 6 month . PROJECTED ACCRUAL : A maximum 60 patient ( 20 per treatment group ) accrue study within 3 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Immunoglobulin G immunoglobulin A ( IgA ) multiple myeloma Low intermediate risk disease base follow criterion : Cytogenetics : translocation , 11q , 13/13q Beta2 microglobulin le 2.5 mg/L first autologous peripheral blood stem cell transplantation ( APBSCT ) Mprotein concentration harvest plasma great 50 % total immunoglobulin correspond isotype ( Mprotein must able purified protein A antiIgAsepharose ) Patients achieve partial complete response first APBSCT eligible Prior/Concurrent Therapy Biologic therapy : See Disease Characteristics No prior APBSCT CD34 select stem cell Chemotherapy : Not specify Endocrine therapy : Steroids must discontinue least 4 week prior vaccination No concurrent steroid Radiotherapy : Not specify Surgery : Not specify Other : Any prior therapy must complete least 8 week prior second APBSCT Recovered toxic effect prior therapy No concurrent aspirin nonsteroidal antiinflammatory drug Patient Characteristics Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 8 week Hepatic : Bilirubin le 2.0 mg/dL rise least 24 week transplantation SGOT great 4 time upper limit normal rise least 24 week transplantation Renal : Creatinine le 2 time normal rise least 24 week transplantation OR Creatinine clearance great 40 mL/min Cardiovascular : LVEF great 50 % MUGA scan Pulmonary : DLCO great 50 % predict Other : No medical condition would increase risk transplantation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>genetic condition</keyword>
	<keyword>hematopoietic/lymphoid cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>multiple myeloma plasma cell neoplasm</keyword>
	<keyword>plasma cell neoplasm</keyword>
	<keyword>refractory plasma cell neoplasm</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage , plasma cell neoplasm</keyword>
</DOC>